Back HIV-Related Conditions Bone Loss IDWeek 2013: HIV+ People Not on Antiretrovirals Are Prone to Inflammation-related Bone Loss

IDWeek 2013: HIV+ People Not on Antiretrovirals Are Prone to Inflammation-related Bone Loss


HIV positive people not taking antiretroviral therapy experienced more bone mineral density (BMD) loss at the hip and were somewhat more likely to develop osteopenia or osteoporosis than HIV negative individuals, researchers reported at the second IDWeek conference held recently in San Francisco. They also found that bone loss among people with HIV appeared to be linked to inflammation.

Research has shown that people with HIV are more prone than HIV negative people to bone loss -- including osteopenia and more severe osteoporosis -- but whether this is attributable to HIV infection itself, resulting inflammatory and metabolic changes, antiretroviral drug toxicity, or a combination of these and other factors is not fully understood.  

Certain antiretrovirals -- notably tenofovir (Viread) and protease inhibitors -- are known to be associated with bone loss, but bone changes in people not yet on antiretroviral therapy (ART) have not been extensively studied. The role of inflammation and vitamin D in bone health is unclear and may be easier to study in treatment-naive individuals.

Corrilynn Hileman from Case Western Reserve University and colleagues looked at changes in hip and spine bone density over time, progression to osteopenia or osteoporosis, and relationships between bone loss and inflammatory markers and vitamin D levels.

This prospective single-site study included 47 antiretroviral-naive HIV positive adults with CD4 T-cell counts greater than 400 cells/mm3 and 41 healthy HIV negative control subjects matched by sex, age, and race.

Most (about 70%) were men, 69% were African-American, about 30% were white, and the median age was 39 years. People in the HIV positive group had been infected for 4 years on average and the mean CD4 count was 625 cells/mm3. The median body mass index (BMI) was 26 kg/m2. HIV positive people were significantly more likely than HIV negative volunteers to be current smokers (72% vs 15%) and to have hepatitis C (19% vs 2%). People with diabetes or active infections or inflammatory conditions were excluded.

At study entry and 48 weeks later participants underwent DEXA scans of the hip and lumbar spine as well as measurement of vitamin D and inflammation biomarkers including interleukin 6 (IL-6), high sensitivity C-reactive protein (hsCRP), soluble tumor necrosis factor alfa receptors I and II (sTNFR-I and sTNFR-II), and the adhesion molecules sVCAM-1 and sICAM-1.

The HIV positive group had significantly higher baseline levels of IL-6 (3.0 vs 2.2 pg/mL, respectively), sTNFR-II (2434 vs 1965 pg/mL), sVCAM-1 (782 vs 544 ng/mL), and sICAM-1 (300 vs 187 ng/mL), but levels of hsCRP, sTNFR-I, and vitamin D (13 vs 15 ng/mL) were similar.

At baseline the HIV positive and HIV negative groups had similar total hip, femoral neck, trochanter (ball of the hip joint), and spine bone density. In both groups a majority (62% and 68%, respectively) had normal BMD and one-third had osteopenia (T score of -1); 4.4% of HIV positive people and no HIV negative people had osteoporosis (T-score of -2.5), but this difference was not significant.


  • Between baseline and 48 weeks, levels of vitamin D and inflammation biomarker levels did not change significantly in either group, nor did changes differ significantly between the 2 groups.
  • Over 48 weeks HIV positive people showed a larger percentage BMD loss at the total hip, trochanter and spine, while HIV negative people lost more at the femoral neck, but none of these differences reached statistical significance.
  • At 48 weeks 93% of people with HIV experienced bone loss at any site, compared with 73% of HIV negative people, a difference that was significant after adjusting for sex, age, race, baseline BMI, smoking, and hepatitis C status.
  • This was particularly notable at the trochanter, with 73% and 49%, respectively, showing bone loss, also significant after adjustment.
  • Being HIV positive conferred a greater likelihood of trochanter BMD loss, with an odds ratio (OR) of 2.8, or nearly 3-fold higher risk.
  • Adding IL-6, sTNFR-II, sVCAM-1, sICAM-1 or vitamin D to the analysis along with HIV status reduced the OR by more than 10%, suggesting inflammation may explain part of the effect of HIV.
  • Over 48 weeks 21% of HIV positive people progressed to osteopenia or osteoporosis compared with 6% of HIV negative individuals, but the difference did not reach statistical significance.
  • The only independent predictors of progression in an adjusted analysis were white race and higher baseline IL-6 level.

"ART-naive HIV+ adults, but not [HIV negative] controls, had BMD loss at the total hip and trochanter sites over 48 weeks," the researchers concluded.

"HIV+ [people] were more likely to have bone loss at the trochanter site and this appears to be associated with systemic inflammation," they added. "In HIV+ [people], IL-6 was independently associated with progression to osteopenia/osteoporosis."



CO Hileman, DELabbato, NJ Storer, and GA Mccomsey. Inflammation, Vitamin D and Change in Bone Mineral Density (BMD) in Antiretroviral Therapy (ART)-Naïve HIV-infected and Uninfected Adults -- A 48-Week Matched Prospective Cohort Study. 2nd IDWeek Conference (IDWeek 2013). San Francisco. October 2-6, 2013.Abstract 674.